---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-092065"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2022-03-31T23:59:59+00:00"
generated_at: "2026-06-26T12:15:57.077979+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CFO Peter Pfreundschuh to depart Frequency Therapeutics March 31, 2022; no successor named

## Summary
- CFO Peter P. Pfreundschuh stepping down effective March 31, 2022; not due to any disagreement with the Company.
- Severance includes 12 months base salary, $189,000 bonus, $20,000 relocation, and COBRA premium payments.
- As of separation, 74,790 stock options are vested and exercisable; 330,210 shares remain unvested.
- No replacement CFO has been announced; CEO David Lucchino signed the separation agreement.
- Separation agreement includes standard release of claims, confidentiality, and non-disparagement clauses.

## SEC filing metadata
- accession: 0001193125-22-092065
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2022-03-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000119312522092065/0001193125-22-092065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000119312522092065/d309564d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-092065
- JSON: https://secwatch.observer/filing/0001193125-22-092065.json
- Plain text: https://secwatch.observer/filing/0001193125-22-092065.txt

## Key facts
- Executive change
  Peter P. Pfreundschuh departed as Chief Financial Officer at Korro Bio, Inc..
  - Action: stepped down
  - Role: Chief Financial Officer
  source text: On March 25, 2022, Peter P. Pfreundschuh notified Frequency Therapeutics, Inc. (the “Company”) that he was stepping down as Chief Financial Officer of the Company, effective March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703647/000119312522092065/0001193125-22-092065-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.